Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Nash

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Clinical Therapeutics|October 7, 2022
Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United StatesSwapna Karkare, Maryia Zhdanava, Dominic Pilon, et al.
Inquiry : a Journal of Medical Care Organization, Provision and Financing|January 1, 1985
A computer-aided system for planning acute care bed need in MichiganJ B Martin, W L Wellman, K J Whipple, et al.
Journal of Affective Disorders|March 30, 2022
Characteristics and current standard of care among veterans with major depressive disorder in the United States: A real-world data analysisXiaohui Zhao, Swapna Karkare, Abigail I Nash, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 25, 2011
Structural basis of photosensitivity in a bacterial light-oxygen-voltage/helix-turn-helix (LOV-HTH) DNA-binding proteinAbigail I Nash, Reginald McNulty, Mary Elizabeth Shillito, et al.
Biochemistry|February 18, 2011
Modulating LOV domain photodynamics with a residue alteration outside the chromophore binding siteSang-Hun Song, Peter L Freddolino, Abigail I Nash, et al.
Pharmacoeconomics|May 27, 2021
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USAMaryia Zhdanava, Jennifer Voelker, Dominic Pilon, et al.
BMC Psychiatry|August 11, 2023
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidalityDong-Jing Fu, Qiaoyi Zhang, Ling Shi, et al.
Journal of Clinical Psychopharmacology|August 19, 2021
Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or BehaviorCarla M Canuso, Dawn F Ionescu, Xiang Li, et al.
Biomolecules|February 25, 2023
Commonly Used Therapeutics Associated with Changes in Arousal Inhibit GABA<sub>A</sub>R ActivationAnling Kaplan, Abigail I Nash, Amanda A H Freeman, et al.
The Journal of Clinical Psychiatry|July 21, 2021
Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM StudiesIbrahim Turkoz, Ella Daly, Jaskaran Singh, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Clinical Therapeutics|October 7, 2022
Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United StatesSwapna Karkare, Maryia Zhdanava, Dominic Pilon, et al.
Inquiry : a Journal of Medical Care Organization, Provision and Financing|January 1, 1985
A computer-aided system for planning acute care bed need in MichiganJ B Martin, W L Wellman, K J Whipple, et al.
Journal of Affective Disorders|March 30, 2022
Characteristics and current standard of care among veterans with major depressive disorder in the United States: A real-world data analysisXiaohui Zhao, Swapna Karkare, Abigail I Nash, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 25, 2011
Structural basis of photosensitivity in a bacterial light-oxygen-voltage/helix-turn-helix (LOV-HTH) DNA-binding proteinAbigail I Nash, Reginald McNulty, Mary Elizabeth Shillito, et al.
Biochemistry|February 18, 2011
Modulating LOV domain photodynamics with a residue alteration outside the chromophore binding siteSang-Hun Song, Peter L Freddolino, Abigail I Nash, et al.
Pharmacoeconomics|May 27, 2021
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USAMaryia Zhdanava, Jennifer Voelker, Dominic Pilon, et al.
BMC Psychiatry|August 11, 2023
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidalityDong-Jing Fu, Qiaoyi Zhang, Ling Shi, et al.
Journal of Clinical Psychopharmacology|August 19, 2021
Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or BehaviorCarla M Canuso, Dawn F Ionescu, Xiang Li, et al.
Biomolecules|February 25, 2023
Commonly Used Therapeutics Associated with Changes in Arousal Inhibit GABA<sub>A</sub>R ActivationAnling Kaplan, Abigail I Nash, Amanda A H Freeman, et al.
The Journal of Clinical Psychiatry|July 21, 2021
Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM StudiesIbrahim Turkoz, Ella Daly, Jaskaran Singh, et al.
Pageof 4